Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by biorunon Sep 26, 2022 9:13am
179 Views
Post# 34985968

Financial reporting this week

Financial reporting this weekThere seems to be a lot of speculation on the "upfront" payment and associated expectations.

Me, like everyone here, is hoping this weeks information is going to put "smiles on all our faces".

If you recall, that would also consider the milestone payments as part of that smile package according to the CEO, so nobody should expect only the first payment to do the trick in my opinion. Milestone payments come at some point later. I am not going to be "niaive" enough to think that just the upfront payment is going to be solely responsible for the overall reaction here. If it does, then all the better.

If the CFO in fact issues a forward looking company wide revenue forecast, we might in fact see the whole piece while we wait for revenues to accrue from the royalties.

If no forecast, then, well, we will just know then an additional piece of the puzzle.

Jimmy, I believe Tickle was referring to Howard and nobody else. It seems you think otherwise. Tread carefully. We are all here to offer our own personal views respectively and that is the purpose of a discussion board. 


<< Previous
Bullboard Posts
Next >>